Business Standard

Friday, December 20, 2024 | 05:35 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Hyderabad-based Biological E joins hands with J&J for Covid-19 vaccine

The vaccine candidate is in phase 1/2a clinical trials

Coronavirus, vaccine, covid, drugs, Sepsivac, clinical trials
Premium

Biological E is going to use its manufacturing infrastructure to support J&J's global commitment to global access for its Covid-19 vaccine

Sohini Das Mumbai
Hyderabad-based pharma company  Biological E Limited (BE) has entered into an agreement with Janssen Pharmaceuticals for the development and manufacturing of Covid-19 drugs as well as Johnson &Johnson's (J&J) Covid-19 vaccine candidate.
 
The vaccine candidate is in phase 1/2a clinical trials.
 
Managing Director of Biological E, Mahima Datla said, "We are very pleased indeed to collaborate with an organisation like Johnson & Johnson. Given the magnitude of the Covid-19 pandemic, our ability to mount an effective response will be predicated on the ability to supply the vaccine globally and in significant quantities. This is best achieved through collaboration."
 
Biological E

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in